
<ns0:uwmetadata xmlns:ns0="http://phaidra.univie.ac.at/XML/metadata/V1.0" xmlns:ns1="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0" xmlns:ns10="http://phaidra.univie.ac.at/XML/metadata/provenience/V1.0" xmlns:ns11="http://phaidra.univie.ac.at/XML/metadata/provenience/V1.0/entity" xmlns:ns12="http://phaidra.univie.ac.at/XML/metadata/digitalbook/V1.0" xmlns:ns13="http://phaidra.univie.ac.at/XML/metadata/etheses/V1.0" xmlns:ns2="http://phaidra.univie.ac.at/XML/metadata/extended/V1.0" xmlns:ns3="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/entity" xmlns:ns4="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/requirement" xmlns:ns5="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/educational" xmlns:ns6="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/annotation" xmlns:ns7="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/classification" xmlns:ns8="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/organization" xmlns:ns9="http://phaidra.univie.ac.at/XML/metadata/histkult/V1.0">
  <ns1:general>
    <ns1:identifier>o:1504</ns1:identifier>
    <ns1:title language="sr">Sinergistički efekat blokade IL-33/ST2 i PDL/PD-1 osovina na progresiju mišjeg karcinoma dojke</ns1:title>
    <ns2:alt_title language="sr">Synergistical effect of IL-33/ST2 and PDL/PD-1 blockage in a mammary carcinoma : doctoral dissertation</ns2:alt_title>
    <ns1:language>sr</ns1:language>
    <ns1:description language="sr">Iako je dobro poznato da pojedinačna blokada bilo PDL/PD-1 bilo IL-33/ST2 osovinedoprinosi efikasnijem anti-tumorskom odgovoru, simulantana blokada ovih osovinanije još uvek izučena. Indukovali smo karcinom dojke (4T1) ili karcinom kolona(ST26) BALB/c ili BALB/c ST2 nokaut miševima, a potom su dobijali anti PD-1 ilianti IL-33 antitelo Simultana blokada IL33/ST2 i PDL/PD1 je odložila pojavupalpabilnog tumora i usporila rast tumora. Naši rezultati takođe ukazuju pojačanucitotoksičnost NK ćelija prema 4T1 tumorskim ćelijama kod ST2 nokaut miševa koji sutretirani anti-PD-1 anitelom. Kod ST2 nokaut miševa koji su tretirani anti-PD-1anitelom je takođe bila povećana ekspresija miRNA-150 i miRNA-155, povećanjeekspresije NFκB i STAT3, povećana ekspresija aktivacionih markera i smanjenaekspresija imunsupresivnih markera kod NK, NKT, T limoficita, u slezini i uprimarnom tumoru. Takođe, NK ćelije izolovane iz BALB/cST2 nokaut miševa koji sutretirani anti-PD-1 anitelom, imaju veči stepen proliferacije i manji stepen apoptozeu primarnom tumoru. Akumulacija imusupresivnih ćelijskih populacija mijeloidnihsupresorskih ćelija il iT regulatornih limfocita, je kod ST2 nokaut miševa koji sutretirani anti-PD-1 anitelom bila značajno manja i u slezini i uz priamrnom tumoru.Ovi rezultati pokazuj uda simultana blokada IL-33/ST2 i PDL/PD-1 osovina mnogoefikasnije usporava progresiju tumora u odnosu na pojedinačnu blokadu, otvarajućinove mogućnosti za terapijski pristum lečenju karcinoma.</ns1:description>
    <ns1:description language="en">Although separate blockage of either IL-33/ST2 or PDL/PD-1 axes has been shown to bebeneficial in many tumors, co-blockage of IL33/ST2 and PDL/PD-1 hasn’t been studied yet.4T1 breast cancer and CT26 colon cancer were inducted in BALB/C wild type (WT) andBALB/C ST2 knockout mice, after which mice underwent anti PD1 and anti IL-33 treatment.Co-blockage of IL33/ST2 and PDL/PD1 delayed tumor appearance and slowed tumor growth.Enhanced NK cell cytotoxicity against 4T1 tumor cells in ST2 knockout anti-PD1 treated micewas associated with overexpression of miRNA-150 and miRNA-155, upregulation of NFκB andSTAT3, increased expression of activation markers and decreased expression ofimmunosuppressive markers in splenic and primary tumor derived NK cells. NK cells from ST2knockout anti-PD1 treated mice tend to proliferate more and are less prone to apoptosis.Accumulation of immunosuppressive myeloid derived suppressor cells and regulatory T cellswas significantly impaired in spleen and primary tumor of ST2 knockout anti-PD1 treated mice.Co-blockage of IL-33/ST2 and PDL/PD-1 axes impedes tumor progression more efficiently thansingle blockage of either axes, thus offering potential new approach to immunotherapy oftumors.</ns1:description>
    <ns1:description language="sr">-</ns1:description>
    <ns2:identifiers>
      <ns2:resource>91552100</ns2:resource>
      <ns2:identifier>62048009</ns2:identifier>
    </ns2:identifiers>
    <ns2:identifiers>
      <ns2:resource>91552101</ns2:resource>
      <ns2:identifier>8553</ns2:identifier>
    </ns2:identifiers>
  </ns1:general>
  <ns1:lifecycle>
    <ns1:upload_date>2022-08-05T12:21:40.053Z</ns1:upload_date>
    <ns1:status>45</ns1:status>
    <ns2:peer_reviewed>no</ns2:peer_reviewed>
    <ns1:contribute seq="0">
      <ns1:role>46</ns1:role>
      <ns1:entity seq="0">
        <ns3:firstname> Marina, 1991-</ns3:firstname>
        <ns3:lastname>Jovanović</ns3:lastname>
        <ns3:conor>63060233</ns3:conor>
      </ns1:entity>
      <ns1:date>2021</ns1:date>
    </ns1:contribute>
    <ns1:contribute seq="1">
      <ns1:role>63</ns1:role>
      <ns1:ext_role>mentor</ns1:ext_role>
      <ns1:entity seq="0">
        <ns3:firstname> Ivan, 1977-</ns3:firstname>
        <ns3:lastname>Jovanović</ns3:lastname>
        <ns3:conor>3999847</ns3:conor>
      </ns1:entity>
      <ns1:date>2021</ns1:date>
    </ns1:contribute>
    <ns1:contribute seq="2">
      <ns1:role>63</ns1:role>
      <ns1:ext_role>predsednik komisije</ns1:ext_role>
      <ns1:entity seq="0">
        <ns3:firstname> Nebojša, 1958-</ns3:firstname>
        <ns3:lastname>Arsenijević</ns3:lastname>
        <ns3:conor>13557351</ns3:conor>
      </ns1:entity>
      <ns1:date>2021</ns1:date>
    </ns1:contribute>
    <ns1:contribute seq="3">
      <ns1:role>63</ns1:role>
      <ns1:ext_role>član komisije</ns1:ext_role>
      <ns1:entity seq="0">
        <ns3:firstname> Gordana, 1976-</ns3:firstname>
        <ns3:lastname>Radosavljević</ns3:lastname>
        <ns3:conor>13591143</ns3:conor>
      </ns1:entity>
      <ns1:date>2021</ns1:date>
    </ns1:contribute>
    <ns1:contribute seq="4">
      <ns1:role>63</ns1:role>
      <ns1:ext_role>član komisije</ns1:ext_role>
      <ns1:entity seq="0">
        <ns3:firstname> Milan, 1963-</ns3:firstname>
        <ns3:lastname>Jovanović</ns3:lastname>
        <ns3:conor>12625511</ns3:conor>
      </ns1:entity>
      <ns1:date>2021</ns1:date>
    </ns1:contribute>
  </ns1:lifecycle>
  <ns1:technical>
    <ns1:format>142 lista</ns1:format>
    <ns1:size>4996159</ns1:size>
    <ns1:location>http://phaidrakg.kg.ac.rs/o:1504</ns1:location>
  </ns1:technical>
  <ns1:rights>
    <ns1:cost>no</ns1:cost>
    <ns1:copyright>yes</ns1:copyright>
    <ns1:license>12</ns1:license>
  </ns1:rights>
  <ns1:annotation>
    <ns6:annotations>
      <ns6:date>2022-08-05T12:21:40.320Z</ns6:date>
    </ns6:annotations>
  </ns1:annotation>
  <ns1:classification>
    <ns1:purpose>70</ns1:purpose>
    <ns7:keyword language="sr" seq="1">IL-33/ST2, PDL-PD/1, karcinom kolona, karcinom dojke, miRNA</ns7:keyword>
    <ns7:keyword language="sr" seq="1">PDL/PD-1, IL-33/ST2, breast carcinoma, colon carcinoma, miRNAs</ns7:keyword>
    <ns7:keyword language="sr" seq="1">618.19-006.6(043.3)</ns7:keyword>
  </ns1:classification>
  <ns1:organization>
    <ns8:hoschtyp>1738</ns8:hoschtyp>
    <ns8:orgassignment>
      <ns8:faculty>34A05</ns8:faculty>
    </ns8:orgassignment>
  </ns1:organization>
  <ns12:digitalbook>
    <ns12:releaseyear>2021</ns12:releaseyear>
  </ns12:digitalbook>
</ns0:uwmetadata>
